UBE2I — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3331112	0.78	17/20
SCHEMBL3719963	0.50	10/20
SCHEMBL6380469	0.51	7/20
SCHEMBL6372842	0.50	7/20
SCHEMBL4787894	0.61	4/20
SCHEMBL6372925	0.53	4/20
SCHEMBL6722070	0.53	4/20
SCHEMBL10117051	0.53	4/20
SCHEMBL6722119	0.45	4/20
SCHEMBL6722180	0.44	4/20
SCHEMBL6981812	0.73	3/20
SCHEMBL4787299	0.63	3/20
SCHEMBL8164257	0.61	3/20
SCHEMBL6316303	0.54	3/20
SCHEMBL3713561	0.52	3/20
SCHEMBL1561830	0.52	3/20
SCHEMBL1562255	0.50	3/20
SCHEMBL6372674	0.47	3/20
SCHEMBL675853	0.47	3/20
SCHEMBL5319354	0.47	3/20

Clinical trials — most relevant to UBE2I by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene Mutation	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis	PHASE1	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome	nan	RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders	nan	RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature.	nan	UNKNOWN
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
ADAPT: Efficacy of a Dietary Supplement During and After Exercise	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a UBE2I binder may also engage these)

Protein	Name	Similarity
P63281	—	1.000	P63281 →
P63280	—	1.000	P63280 →
Q28CQ4	—	1.000	Q28CQ4 →
P63283	—	1.000	P63283 →
Q2EF73	—	1.000	Q2EF73 →
P40984	—	1.000	P40984 →
Q9W6H5	—	1.000	Q9W6H5 →
P63282	—	1.000	P63282 →
O09181	—	1.000	O09181 →
Q6Y1Z4	—	1.000	Q6Y1Z4 →
Q96UP5	—	1.000	Q96UP5 →
Q95017	—	1.000	Q95017 →
P49459	—	1.000	P49459 →
Q4WLA7	—	0.999	Q4WLA7 →
P63149	—	0.999	P63149 →
P25865	—	0.998	P25865 →
Q9DDJ0	—	0.998	Q9DDJ0 →
Q86IZ3	—	0.997	Q86IZ3 →
UBE2B	Ubiquitin-conjugating enzyme E2 B	0.997	landscape →
UBE2N	Ubiquitin-conjugating enzyme E2 N	0.995	landscape →
Q0P5K3	—	0.995	Q0P5K3 →
Q9EQX9	—	0.995	Q9EQX9 →
Q9CY34	—	0.995	Q9CY34 →
P78717	—	0.995	P78717 →
Q553F3	—	0.995	Q553F3 →
O74201	—	0.995	O74201 →
Q9P6I1	—	0.994	Q9P6I1 →
Q4R4I1	—	0.994	Q4R4I1 →
Q42551	—	0.994	Q42551 →
Q5JXB2	—	0.994	Q5JXB2 →